Ventricular arrhythmias: From the electrophysiology laboratory to clinical practice. Part II: Potentially malignant and benign ventricular arrhythmias

Hellenic Journal of Cardiology

Volumn 53, Issue 3, 2012, Pages 217-233

  Gatzoulis, Konstantinos A ^a   Archontakis, Stefanos ^a   Dilaveris, Polychronis ^a   Tsiachris, Dimitrios ^a   Arsenos, Petros ^a   Sideris, Skevos ^b   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Automatic implantable cardioverter defibrillators; Electrophysiological study; Malignant ventricular tachyarrhythmias; Risk stratification for sudden cardiac death

Indexed keywords

AMIODARONE; PLACEBO;

BENIGN HEART VENTRICLE ARRHYTHMIA; CARDIOLOGIST; CARDIOVASCULAR RISK; CATHETER ABLATION; CLINICAL PRACTICE; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; DISEASE MARKER; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART DEATH; HEART ELECTROPHYSIOLOGY; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE ANEURYSM; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IDIOPATHIC HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MALIGNANT HEART VENTRICLE ARRHYTHMIA; MEDICAID; MEDICARE; NONHUMAN; PROGNOSIS; REVIEW; SUDDEN DEATH; SYNCOPE; TACHYCARDIA;

ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HEART DEFECTS, CONGENITAL; HEART FAILURE; HUMANS;

EID: 84865841005     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (179)

1. Gatzoulis KA, Archontakis S, Dilaveris P, et al. Ventricular arrhythmias: from the electrophysiology laboratory to clinical practice. Part I: malignant ventricular arrhythmias. Hellenic J Cardiol. 2011; 52: 525-535.
2. Letsas KP, Charalampous C, Weber R, et al. Methods and indications for ablation of ventricular tachycardia. Hellenic J Cardiol. 2011; 52: 427-436.
3. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989; 321: 406-412.
4. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet. 1997; 349: 667-674.
5. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet. 1997; 349: 675-682.
6. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995; 333: 77-82.
7. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994; 344: 493-498.
8. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol. 1992; 20: 1056-1062.
9. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996; 348; 7-12.
10. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996; 335: 1933-1940.
11. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999; 341: 1882-1890.
12. Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol. 1991; 18: 687-697.
13. Turitto G, Fontaine JM, Ursell S, Caref EB, Bekheit S, el-Sherif N. Risk stratification and management of patients with organic heart disease and nonsustained ventricular tachycardia: role of programmed stimulation, left ventricular ejection fraction, and the signal-averaged electrocardiogram. Am J Med. 1990; 88: 35N-41N.
14. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 2000; 342: 1937-1945.
15. Villacastín J, Almendral J, Arenal A, et al. Incidence and clinical significance of multiple consecutive, appropriate, high-energy discharges in patients with implanted cardioverter-defibrillators. Circulation. 1996; 93: 753-762.
16. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002; 346: 877-883.
17. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352: 225-237.
18. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004; 292: 2874-2879.
19. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997; 337: 1569-1575.
20. Koplan BA, Stevenson WG. Ventricular tachycardia and sudden cardiac death. Mayo Clin Proc. 2009; 84: 289-297.
21. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009; 361: 1427-1436.
22. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004; 351: 2481-2488.
23. Al-Khatib SM, Hafley G, Lee KL, Buxton AE. Relation between time from myocardial infarction to enrolment and patient outcomes in the Multicenter UnSustained Tachycardia Trial. Europace. 2010; 12: 1112-1118.
24. Curtis JP, Sokol SI, Wang Y, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol. 2003; 42: 736-742.
25. Ding L, Hua W, Niu H, Chen K, Zhang S. Primary prevention of sudden cardiac death using implantable cardioverter defibrillators. Europace. 2008; 10: 1034-1041.
26. Buxton AE, Moss AJ. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Circulation. 2005; 111: 2537-2549.
27. Goldenberg I, Vyas AK, Hall WJ, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008; 51: 288-296.
28. Buxton AE, Lee KL, Hafley GE, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007; 50: 1150-1157.
29. Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJ. Out-of-hospital cardiac arrest-the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J. 2003; 24: 1204-1209.
30. Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol. 2006; 47: 1161-1166.
31. el-Sherif N, Denes P, Katz R, et al. Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period. The Cardiac Arrhythmia Suppression Trial/Signal-Averaged Electrocardiogram (CAST/SAECG) Substudy Investigators. J Am Coll Cardiol. 1995; 25: 908-914.
32. Gomes JA, Cain ME, Buxton AE, Josephson ME, Lee KL, Hafley GE. Prediction of long-term outcomes by signal-averaged electrocardiography in patients with unsustained ventricular tachycardia, coronary artery disease, and left ventricular dysfunction. Circulation. 2001; 104: 436-441.
33. Andresen D, Steinbeck G, Brüggemann T, et al. Risk stratification following myocardial infarction in the thrombolytic era: a two-step strategy using noninvasive and invasive methods. J Am Coll Cardiol. 1999; 33: 131-138.
34. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: signal-averaged electrocardiogram, Holter monitoring and radionuclide ventriculography. J Am Coll Cardiol. 1987; 9: 531-538.
35. Huikuri HV, Tapanainen JM, Lindgren K, et al. Prediction of sudden cardiac death after myocardial infarction in the betablocking era. J Am Coll Cardiol. 2003; 42: 652-658.
36. Gatzoulis KA, Carlson MD, Biblo LA, et al. Time domain analysis of the signal averaged electrocardiogram in patients with a conduction defect or a bundle branch block. Eur Heart J. 1995; 16: 1912-1919.
37. Rosenbaum DS, Jackson LE, Smith JM, Garan H, Ruskin JN, Cohen RJ. Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med. 1994; 330: 235-241.
38. Gold MR, Bloomfield DM, Anderson KP, et al. A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. J Am Coll Cardiol. 2000; 36: 2247-2253.
39. Rosenbaum DS. T-wave alternans in the sudden cardiac death in heart failure trial population: signal or noise? Circulation. 2008; 118: 2015-2018.
40. Costantini O, Hohnloser SH, Kirk MM, et al. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol. 2009; 53: 471-479.
41. Giannopoulos G, Dilaveris P, Batchvarov V, et al. Prognostic significance of inverse spatial QRS-T angle circadian pattern in myocardial infarction survivors. J Electrocardiol. 2009; 42: 79-84.
42. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation. 1998; 98: 1510-1516.
43. Chow T, Kereiakes DJ, Bartone C, et al. Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2006; 47: 1820-1827.
44. Sawhney N, Narayan SM. Sudden cardiac arrest in patients with preserved left ventricular systolic function: a clinical dilemma. Heart Rhythm. 2009; 6: S15-21.
45. La Rovere MT, Pinna GD, Maestri R, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation. 2003; 107: 565-570.
46. Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol. 1991; 18: 687-697.
47. Ikeda T, Yoshino H, Sugi K, et al. Predictive value of microvolt T-wave alternans for sudden cardiac death in patients with preserved cardiac function after acute myocardial infarction: results of a collaborative cohort study. J Am Coll Cardiol. 2006; 48: 2268-2274.
48. Hsia J, Jablonski KA, Rice MM, et al. Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function. Am J Cardiol. 2008; 101: 457-461.
49. Sanders GD, Kong MH, Al-Khatib SM, Peterson ED. Costeffectiveness of implantable cardioverter defibrillators in patients >or=65 years of age. Am Heart J. 2010; 160: 122-131.
50. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005; 353: 1471-1480.
51. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999; 341: 1882-1890.
52. Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008; 51: 1357-1365.
53. Alter P, Waldhans S, Plachta E, Moosdorf R, Grimm W. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol. 2005; 28: 926-932.
54. Marian AJ. On predictors of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003; 41: 994-996.
55. Maron BJ, McKenna WJ, Danielson G, et al. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy. Eur Heart J. 2003; 24: 1965-1991.
56. Primo J, Geelen P, Brugada J, et al. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J Am Coll Cardiol. 1998; 31: 1081-1085.
57. Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 2003; 26: 1887-1896.
58. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000; 342: 365-373.
59. Zhu DW, Sun H, Hill R, Roberts R. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 1998; 21: 299-302.
60. Maron BJ. Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator. Eur Heart J. 2000; 21: 1979-1983.
61. Kuck KH. Arrhythmias in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 1997; 20: 2706-2713.
62. Christiaans I, van Engelen K, van Langen IM, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace. 2010; 12: 313-321.
63. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation. 1994; 90: 2743-2747.
64. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart. 2002; 87: 169-176.
65. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol. 2003; 41: 987-993.
66. Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009; 119: 1703-1710.
67. McKenna WJ, Sharma S, Elliott PM. Management strategies in hypertrophic cardiomyopathy: influence of age and morphology. Eur Heart J. 2001; 3 (Suppl L): L10-L14.
68. Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003; 41: 315-321.
69. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000; 36: 2212-2218.
70. Frenneaux MP. Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart. 2004; 90: 570-575.
71. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/ NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices. Summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2002; 106: 2145-2161.
72. Maron BJ, Spirito P. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2008; 19: 1118-1126.
73. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007; 298: 405-412.
74. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/ HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/ AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008; 51: e1-62.
75. Grimm W, Christ M, Bach J, Müller HH, Maisch B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation. 2003; 108: 2883-2891.
76. Meyer C, Schueller P, Rodenbeck A, et al. Primary and secondary prevention of ventricular arrhythmias in dilated cardiomyopathy: nonsustained, sustained, and incessant. Int Heart J. 2009; 50: 741-751.
77. Schaer BA, Ammann P, Sticherling C, Zellweger MJ, Cron TA, Osswald S. Prophylactic implantable cardioverter defibrillator therapy in dilated cardiomyopathy: impact of left ventricular function. Int J Cardiol. 2006; 108: 26-30.
78. Grimm W, Hoffmann J, Menz V, Luck K, Maisch B. Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia. J Am Coll Cardiol. 1998; 32: 739-745.
79. Rinaldi CA, Simon RD, Baszko A, et al. Can we predict which patients with implantable cardioverter defibrillators receive appropriate shock therapy? A study of 155 patients. Int J Cardiol. 2003; 88: 69-75.
80. Rankovic V, Karha J, Passman R, Kadish AH, Goldberger JJ. Predictors of appropriate implantable cardioverter-defibrillator therapy in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2002; 89: 1072-1076.
81. Hsia HH, Marchlinski FE. Electrophysiology studies in patients with dilated cardiomyopathies. Card Electrophysiol Rev. 2002; 6: 472-481.
82. Brilakis ES, Shen WK, Hammill SC, et al. Role of programmed ventricular stimulation and implantable cardioverter defibrillators in patients with idiopathic dilated cardiomyopathy and syncope. Pacing Clin Electrophysiol. 2001; 24: 1623-1630.
83. Chen X, Shenasa M, Borggrefe M, et al. Role of programmed ventricular stimulation in patients with idiopathic dilated cardiomyopathy and documented sustained ventricular tachyarrhythmias: inducibility and prognostic value in 102 patients. Eur Heart J. 1994; 15: 76-82.
84. Brilakis ES, Friedman PA, Maounis TN, et al. Programmed ventricular stimulation in patients with idiopathic dilated cardiomyopathy and syncope receiving implantable cardioverter-defibrillators: a case series and a systematic review of the literature. Int J Cardiol. 2005; 98: 395-401.
85. Stamato NJ, O'Connell JB, Murdock DK, Moran JF, Loeb HS, Scanlon PJ. The response of patients with complex ventricular arrhythmias secondary to dilated cardiomyopathy to programmed electrical stimulation. Am Heart J. 1986; 112: 505-508.
86. Rolf S, Haverkamp W, Borggrefe M, Breithardt G, Bocker D. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis. Europace. 2009; 11: 289-296.
87. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004; 350: 2151-2158.
88. Poll DS, Marchlinski FE, Buxton AE, Josephson ME. Usefulness of programmed stimulation in idiopathic dilated cardiomyopathy. Am J Cardiol. 1986; 58: 992-997.
89. Meinertz T, Treese N, Kasper W, et al. Determinants of prognosis in idiopathic dilated cardiomyopathy as determined by programmed electrical stimulation. Am J Cardiol. 1985; 56: 337-341.
90. Das SK, Morady F, DiCarlo L, et al. Prognostic usefulness of programmed ventricular stimulation in idiopathic dilated cardiomyopathy without symptomatic ventricular arrhythmias. Am J Cardiol. 1986; 58: 998-1000.
91. Gössinger HD, Jung M, Wagner L, et al. Prognostic role of inducible ventricular tachycardia in patients with dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia. Int J Cardiol. 1990; 29: 215-220.
92. Brembilla-Perrot B, Donetti J, de la Chaise AT, Sadoul N, Aliot E, Juillière Y. Diagnostic value of ventricular stimulation in patients with idiopathic dilated cardiomyopathy. Am Heart J. 1991; 121: 1124-1131.
93. Gatzoulis KA, Salourou M, Dilaveris P, et al. Programmed ventricular stimulation as a risk stratifier for the primary prevention of sudden cardiac death among dilated cardiomyopathy patients. Eur Heart J. 2009; Abstract book, P4-149 (abstr).
94. Daubert JP, Winters SL, Subacius H, et al. Ventricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic cardiomyopathy patients: a DEFINITE substudy. Pacing Clin Electrophysiol. 2009; 32: 755-761.
95. Nazarian S, Bluemke DA, Lardo AC, et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation. 2005; 112: 2821-2825.
96. Bänsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002; 105: 1453-1458.
97. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia- AMIOVIRT. J Am Coll Cardiol. 2003; 41: 1707-1712.
98. Frankenstein L, Zugck C, Nelles M, Schellberg D, Remppis A, Katus H. Primary ICD-therapy in patients with advanced heart failure: selection strategies and future trials. Clin Res Cardiol. 2008; 97: 594-600.
99. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000; 21: 2071-2078.
100. Grimm W, Hoffmann JJ, Muller HH, Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol. 2002; 39: 780-787.
101. Van der Velden LB, Huybrechts W, Adriaensens B, et al. Appropriate and inappropriate implantable cardioverter defibrillator interventions during secondary prevention. Acta Cardiol. 2008; 63: 39-45.
102. Thiene G, Corrado D, Basso C. Arrhythmogenic right ventricular cardiomyopathy/ dysplasia. Orphanet J Rare Dis. 2007; 2: 45.
103. Avramides D, Protonotarios N, Asimaki A, Matsakas E. Arrhythmogenic right ventricular cardiomyopathy/dysplasia. Hellenic J Cardiol. 2011; 52: 452-461.
104. Link MS, Wang PJ, Haugh CJ, et al. Arrhythmogenic right ventricular dysplasia: clinical results with implantable cardioverter defibrillators. J Interv Card Electrophysiol. 1997; 1: 41-48.
105. Wichter T, Paul TM, Eckardt L, et al. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD? Herz. 2005; 30: 91-101.
106. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/ dysplasia. Circulation. 2003; 108: 3084-3091.
107. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J. 1994; 71: 215-218.
108. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997; 30: 1512-1520.
109. Berreklouw E, Hoogsteen J, van Wandelen R, et al. Bilateral mammary artery surgery or percutaneous transluminal coronary angioplasty for multivessel coronary artery disease? An analysis of effects and costs. Eur Heart J. 1989; 10 Suppl H: 61-70.
110. Nava A, Bauce B, Basso C, et al. Clinical profile and longterm follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2000; 36: 2226-2233.
111. Nava A, Folino AF, Bauce B, et al. Signal-averaged electrocardiogram in patients with arrhythmogenic right ventricular cardiomyopathy and ventricular arrhythmias. Eur Heart J. 2000; 21: 58-65.
112. Protonotarios N, Tsatsopoulou A, Anastasakis A, et al. Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos disease) caused by a deletion in plakoglobin. J Am Coll Cardiol. 2001; 38: 1477-1484.
113. Protonotarios NI, Tsatsopoulou AA, Gatzoulis KA. Arrhythmogenic right ventricular cardiomyopathy caused by a deletion in plakoglobin (Naxos disease). Card Electrophysiol Rev. 2002; 6: 72-80.
114. Gatzoulis K, Protonotarios N, Anastasakis A, et al. Implantable defibrillator therapy in Naxos disease. Pacing Clin Electrophysiol. 2000; 23: 1176-1178.
115. O'Donnell D, Cox D, Bourke J, Mitchell L, Furniss S. Clinical and electrophysiological differences between patients with arrhythmogenic right ventricular dysplasia and right ventricular outflow tract tachycardia. Eur Heart J. 2003; 24: 801-810.
116. Wichter T, Paul M, Wollman C, et al: Implantable cardioverter/ defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation. 2004; 109: 1503-1508.
117. Komura M, Suzuki J, Adachi S, et al. Clinical course of arrhythmogenic right ventricular cardiomyopathy in the era of implantable cardioverter-defibrillators and radiofrequency catheter ablation. Int Heart J. 2010; 51: 34-40.
118. Boldt LH, Haverkamp W. Arrhythmogenic right ventricular cardiomyopathy: diagnosis and risk stratification. Herz. 2009; 34: 290-297.
119. Oechslin EN, Harrison DA, Connelly MS, Webb GD, Siu SC. Mode of death in adults with congenital heart disease. Am J Cardiol. 2000; 86: 1111-1116.
120. Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year followup period. Eur Heart J. 2005; 26: 2325-2333.
121. Khairy P, Dore A, Talajic M, et al. Arrhythmias in adult congenital heart disease. Expert Rev Cardiovasc Ther. 2006; 4: 83-95.
122. Perloff JK, Warnes CA. Challenges posed by adults with repaired congenital heart disease. Circulation. 2001; 103: 2637-2643.
123. Triedman JK. Arrhythmias in adults with congenital heart disease. Heart. 2002; 87: 383-389.
124. Gellatt M, Hamilton R, McCrindle B, et al. Arrhythmia and mortality after Mustard: A 30 year single-center experience. J Am Coll Cardiol. 1997; 29: 194-201.
125. Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol. 1998; 32: 245-251.
126. Khairy P, Fernandes SM, Mayer JE, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008; 117: 85-92.
127. Gatzoulis K, Frogoudaki A, Brili S, Stefanadis C. Implantable defibrillators: from the adult cardiac to the grown up congenital heart disease patient. Int J Cardiol. 2004; 97 Suppl 1: 117-122.
128. Shannon KM. Use of implantable cardioverter-defibrillators in pediatric patients. Curr Opin Cardiol. 2002; 17: 280-282.
129. Biblo LA, Carlson MD. Transcatheter radiofrequency ablation of ventricular tachycardia following surgical correction of tetralogy of Fallot. Pacing Clin Electrophysiol. 1994; 17: 1556-1560.
130. Gonska BD, Cao K, Raab J, Eigster G, Kreuzer H. Radiofrequency catheter ablation of right ventricular tachycardia late after repair of congenital heart defects. Circulation. 1996; 94: 1902-1908.
131. Alexander ME, Walsh EP, Saul JP, Epstein MR, Triedman JK. Value of programmed ventricular stimulation in patients with congenital heart disease. J Cardiovasc Electrophysiol. 1999; 10: 1033-1044.
132. Walsh EP. Interventional electrophysiology in patients with congenital heart disease. Circulation. 2007; 115: 3224-3234.
133. Zipes DP, Camm AJ, Borggrefe M, et al. American College of Cardiology/American Heart Association Task Force, European Society of Cardiology Committee for Practice Guidelines, European Heart Rhythm Association the Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J. 2006; 27: 2099-2140.
134. Harrison DA, Harris L, Siu SC, et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol. 1997; 30: 1368-1373.
135. Shen WK, Holmes DR, Porter CJ, McGoon DC, Ilstrup DM. Sudden death after repair of double-outlet right ventricle. Circulation. 1990; 81: 128-136.
136. Nollert G, Fischlein T, Bouterwek S, Bohmer C, Klinner W, Reichart B. Long-term survival in patients with repair of tetralogy of Fallot: 36-year follow-up of 490 survivors of the first year after surgical repair. J Am Coll Cardiol. 1997; 30: 1374-1383.
137. Gatzoulis MA, Till JA, Somerville J, Redington AN. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995; 92: 231-237.
138. Gatzoulis MA, Till JA, Redington AN. Depolarization-repolarization inhomogeneity after repair of tetralogy of Fallot. The substrate for malignant ventricular tachycardia? Circulation. 1997; 95: 401-404.
139. Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000; 356: 975-981.
140. Davos CH, Davlouros PA, Wensel R, et al. Global impairment of cardiac autonomic nervous activity late after repair of tetralogy of Fallot. Circulation. 2002; 106: I69-75.
141. Jonsson H, Ivert T, Brodin LA, Jonasson R. Late sudden deaths after repair of tetralogy of Fallot. Electrocardiographic findings associated with survival. Scand J Thorac Cardiovasc Surg. 1995; 29: 131-139.
142. Hokanson JS, Moller JH. Significance of early transient complete heart block as a predictor of sudden death late after operative correction of tetralogy of Fallot. Am J Cardiol. 2001; 87: 1271-1277.
143. Vogel M, Sponring J, Cullen S, Deanfield JE, Redington AN. Regional wall motion and abnormalities of electrical depolarization and repolarization in patients after surgical repair of tetralogy of Fallot. Circulation. 2001; 103: 1669-1673.
144. Babu-Narayan SV, Kilner PJ, Li W, et al. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of fallot and its relationship to adverse markers of clinical outcome. Circulation. 2006; 113: 405-413.
145. Ghai A, Silversides C, Harris L, Webb GD, Siu SC, Therrien J. Left ventricular dysfunction is a risk factor for sudden cardiac death in adults late after repair of tetralogy of Fallot. J Am Coll Cardiol. 2002; 40: 1675-1680.
146. Brili S, Aggeli C, Gatzoulis K, et al. Echocardiographic and signal averaged ECG indices associated with non-sustained ventricular tachycardia after repair of tetralogy of fallot. Heart. 2001; 85: 57-60.
147. Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation. 2008; 117: 363-370.
148. Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation. 2004; 109: 1994-2000.
149. Khairy P, Dore A, Poirier N, et al. Risk stratification in surgically repaired tetralogy of Fallot. Expert Rev Cardiovasc Ther. 2009; 7: 755-762.
150. Witte KK, Pepper CB, Cowan JC, Thomson JD, English KM, Blackburn ME. Implantable cardioverter-defibrillator therapy in adult patients with tetralogy of Fallot. Europace. 2008; 10: 926-930.
151. Khairy P, Harris L, Landzberg MJ, et al. Sudden death and defibrillators in transposition of the great arteries with intraatrial baffles: a multicenter study. Circ Arrhythm Electrophysiol. 2008; 1: 250-257.
152. Pettersen E, Helle-Valle T, Edvardsen T, et al. Contraction pattern of the systemic right ventricle shift from longitudinal to circumferential shortening and absent global ventricular torsion. J Am Coll Cardiol. 2007; 49: 2450-2456.
153. Kammeraad JA, van Deurzen CH, Sreeram N, et al. Predictors of sudden cardiac death after Mustard or Senning repair for transposition of the great arteries. J Am Coll Cardiol. 2004; 44: 1095-1102.
154. Kennedy HL, Whitlock JA, Sprague MK, Kennedy LJ, Buckingham TA, Goldberg RJ. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med. 1985; 312: 193-197.
155. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992; 20: 1391-1396.
156. Gussak I, Bjerregaard P, Hammill SC. Clinical diagnosis and risk stratification in patients with Brugada syndrome. J Am Coll Cardiol. 2001; 37: 1635-1638.
157. Schwartz PJ, Locati E. The idiopathic long QT syndrome: pathogenetic mechanisms and therapy. Eur Heart J. 1985; 6 Suppl D: 103-114.
158. Moss AJ, Schwartz PJ, Crampton RS, Locati E, Carleen E. The long QT syndrome: a prospective international study. Circulation. 1985; 71: 17-21.
159. Schwartz PJ, Locati EH, Moss AJ, Crampton RS, Trazzi R, Ruberti U. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. Circulation. 1991; 84: 503-511.
160. Fowler SJ, Cerrone M, Napolitano C, Priori SG. Genetic testing for inherited cardiac arrhythmias. Hellenic J Cardiol. 2010; 51: 92-103.
161. Letsas KP, Weber R, Tsikrikas S, Charalampous C, Arentz T. Atypical Brugada ECG phenotype involving ST-segment elevation in lateral leads. Hellenic J Cardiol. 2010; 51: 563-564.
162. Gatzoulis K, Apostolopoulos T, Vlasseros J, et al. Patients presenting with complex right ventricular ectopy. Do they represent a subclinical form of RV cardiomyopathy? Eur Heart J. 2001; 22: P3732 (abstr).
163. Gregoratos G. Permanent pacemakers in older persons. J Am Geriatr Soc. 1999; 47: 1125-1135.
164. Wollner L, McCarthy ST. Cardiac arrhythmias. Cardiac arrhythmias in the elderly. Br Med J (Clin Res Ed). 1982; 285: 511.
165. Chugh SS, Kelly KL, Titus JL. Sudden cardiac death with ap parently normal heart. Circulation. 2000; 102: 649-654.
166. Dilaveris P, Giannopoulos G, Synetos A, et al. Effect of biventricular pacing on ventricular repolarization and functional indices in patients with heart failure: lack of association with arrhythmic events. Europace. 2009; 11: 741-750.
167. Grines CL, Bashore TM, Boudoulas H, Olson S, Shafer P, Wooley CF. Functional abnormalities in isolated left bundle branch block. The effect of interventricular asynchrony. Circulation. 1989; 79: 845-853.
168. Nishimura RA, Hayes DL, Holmes DR, Tajik AJ. Mechanism of hemodynamic improvement by dual-chamber pacing for severe left ventricular dysfunction: an acute Doppler and catheterization hemodynamic study. J Am Coll Cardiol. 1995; 25: 281-288.
169. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001; 344: 873-880.
170. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004; 350: 2140-2150.
171. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009; 361: 1329-1338.
172. Daubert C, Gold MR, Abraham WT, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009; 54: 1837-1846.
173. Latif S, Dixit S, Callans DJ. Ventricular arrhythmias in normal hearts. Cardiol Clin. 2008; 26: 367-80, vi.
174. Biffi A, Pelliccia A, Verdile L, et al. Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes. J Am Coll Cardiol. 2002; 40: 446-452.
175. Kennedy HL. Benign ventricular ectopic activity. Cardiac Electrophysiology Review. 1997. 1/2: 90-91.
176. Kim RJ, Iwai S, Markowitz SM, Shah BK, Stein KM, Lerman BB. Clinical and electrophysiological spectrum of idiopathic ventricular outflow tract arrhythmias. J Am Coll Cardiol. 2007; 49: 2035-2043.
177. Takemoto M, Yoshimura H, Ohba Y, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol. 2005; 45: 1259-1265.
178. Deligiannis A, Anastasakis A, Antoniades L, et al. Recommendations for the cardiovascular screening of athletes. Hellenic J Cardiol. 2010; 51: 530-537.
179. Arkolaki EG, Simantirakis EN. Asymptomatic arrhythmias in patients with unexplained syncope: do they have any diagnostic value? Hellenic J Cardiol. 2010; 51: 89-91.